118 related articles for article (PubMed ID: 15922963)
1. In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis.
Shah K; Tung CH; Breakefield XO; Weissleder R
Mol Ther; 2005 Jun; 11(6):926-31. PubMed ID: 15922963
[TBL] [Abstract][Full Text] [Related]
2. Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
[TBL] [Abstract][Full Text] [Related]
3. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.
Shah K; Tang Y; Breakefield X; Weissleder R
Oncogene; 2003 Oct; 22(44):6865-72. PubMed ID: 14534533
[TBL] [Abstract][Full Text] [Related]
4. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
[TBL] [Abstract][Full Text] [Related]
5. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.
Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J
Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708
[TBL] [Abstract][Full Text] [Related]
6. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma.
Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ
Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304
[TBL] [Abstract][Full Text] [Related]
7. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML; Croxton R; Krajewska M; Krajewski S; Kress CL; Lu M; Suh N; Sporn MB; Cryns VL; Zapata JM; Reed JC
Cancer Res; 2005 Jun; 65(11):4799-808. PubMed ID: 15930300
[TBL] [Abstract][Full Text] [Related]
8. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy.
Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY
Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754
[TBL] [Abstract][Full Text] [Related]
9. Curcumin differentially sensitizes malignant glioma cells to TRAIL/Apo2L-mediated apoptosis through activation of procaspases and release of cytochrome c from mitochondria.
Gao X; Deeb D; Jiang H; Liu YB; Dulchavsky SA; Gautam SC
J Exp Ther Oncol; 2005; 5(1):39-48. PubMed ID: 16416600
[TBL] [Abstract][Full Text] [Related]
10. Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.
Yoo J; Choi S; Hwang KS; Cho WK; Jung CR; Kwon ST; Im DS
J Gene Med; 2006 Feb; 8(2):163-74. PubMed ID: 16144019
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
VanOosten RL; Earel JK; Griffith TS
Cancer Gene Ther; 2006 Jun; 13(6):628-32. PubMed ID: 16456549
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.
Griffith TS; Broghammer EL
Mol Ther; 2001 Sep; 4(3):257-66. PubMed ID: 11545617
[TBL] [Abstract][Full Text] [Related]
14. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.
Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F
Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK; VanOosten RL; Griffith TS
Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
[TBL] [Abstract][Full Text] [Related]
16. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
[TBL] [Abstract][Full Text] [Related]
17. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.
Begue B; Wajant H; Bambou JC; Dubuquoy L; Siegmund D; Beaulieu JF; Canioni D; Berrebi D; Brousse N; Desreumaux P; Schmitz J; Lentze MJ; Goulet O; Cerf-Bensussan N; Ruemmele FM
Gastroenterology; 2006 Jun; 130(7):1962-74. PubMed ID: 16762619
[TBL] [Abstract][Full Text] [Related]
18. Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.
Shah K; Bureau E; Kim DE; Yang K; Tang Y; Weissleder R; Breakefield XO
Ann Neurol; 2005 Jan; 57(1):34-41. PubMed ID: 15622535
[TBL] [Abstract][Full Text] [Related]
19. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
